News

May 8, 2018

Forty Seven’s 5F9 Immunotherapy on FDA Fast Track for DLBCL, Follicular Lymphoma

News

The U.S. Food and Drug Administration has granted fast track status to Forty Seven’s lead candidate Hu5F9-G4 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. ... Read more

May 7, 2018

Arthritis Medication May Prevent GvHD, Side Effect of Stem Cell Transplants, Mouse Study Suggests

News

Baricitinib, a medicine approved in Europe for the treatment for rheumatoid arthritis, both prevented and reverted a life-threatening complication of stem cell transplants called graft-versus-host disease, a study in mice suggests. Notably, ... Read more

May 4, 2018May 4, 2018

Takeda, Nectar Plan to Test New IO Combination in non-Hodgkin Lymphoma Patients

News

Nektar Therapeutics and Takeda Pharmaceutical are working together to evaluate a new therapy combining a lead investigational compound from each company — NKTR-214 and TAK-659N — in people with blood cancers ... Read more

May 3, 2018

FDA Approves Kymriah for Relapsed or Refractory Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory large B-cell lymphoma, Novartis announced. Specifically, the approval of intravenous Kymriah suspension is ... Read more

May 2, 2018

CHMP Recommends Approval of Generic Carmustine for Lymphoma, Brain Tumors

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of the generic medication Carmustine Obvius (carmustine) for the treatment of non-Hodgkin’s lymphoma, Hodgkin’s ... Read more

April 30, 2018April 30, 2018

Dosing Begins in Phase 1 Trial of STRO-001, Potential Lymphoma and Multiple Myeloma Therapy

News

A Phase 1 study of Sutro Biopharma’s STRO-001 treatment candidate for non-Hodgkin’s lymphoma and multiple myeloma has begun dosing patients, the company announced. STRO-001 is an antibody drug conjugate (ADC) that targets ... Read more

April 27, 2018April 27, 2018

FDA Orders Enrollment Hold on Tazemetostat Clinical Trials

News

Patient enrollment for clinical trials of Epizyme’s tazemetostat is temporarily on hold. The decision from the U.S. Food and Drug Administration (FDA) follows a safety report of a pediatric patient ... Read more

April 26, 2018April 26, 2018

Nearly Half of NHL Patients in Phase 1 Trial Respond to ALT-803, Rituxan Combo, Results Show

News

A combination of Rituxan (rituximab) and the experimental agent ALT-803 leads to a response rate of 48% in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma, according to preliminary data from a Phase ... Read more

April 24, 2018

Phase 2 ACCEPT Trial Explores Adding Acalabrutinib to Standard DLBCL Treatment

News

A Phase 2 clinical trial, ACCEPT, is designed to determine if adding acalabrutinib to standard, first-line R-CHOP chemotherapy will benefit patients with diffuse large B-cell lymphoma (DLBCL). The trial, ongoing ... Read more

April 23, 2018

Some Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma Patients Respond Well to Tazemetostat in Phase 1 Trial

News

The investigational EZH2 inhibitor tazemetostat was safe and shrank tumors in 38 percent of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma who were included in the first part of a ... Read more